<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2023000300140</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.23000030</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Low dose nivolumab in metastatic mucosal melanoma: a case report]]></article-title>
<article-title xml:lang="es"><![CDATA[Dosis baja de nivolumab en melanoma mucoso metastásico: reporte de caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meraz-Brenez]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarrete-Reyes]]></surname>
<given-names><![CDATA[Ana P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ignacio-Álvarez]]></surname>
<given-names><![CDATA[Eleazar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Anguiano]]></surname>
<given-names><![CDATA[Georgina J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Verduzco-Aguirre]]></surname>
<given-names><![CDATA[Haydee C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Department of Hemato-Oncology ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Geriatric Service ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Nuclear Medicine Service ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Otorhinolaryngology Service ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>22</volume>
<numero>3</numero>
<fpage>140</fpage>
<lpage>145</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2023000300140&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2023000300140&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2023000300140&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract We present the case of a 77-year-old man with metastatic mucosal melanoma, unable to afford standard doses of immunotherapy, who was treated with nivolumab at a lower dose of 0.5 mg/kg every 2 weeks. Drug activity was demonstrated through both objective tumor response and an immune-related adverse event. This suggests that a lower dose of nivolumab could be a viable alternative for patients with advanced mucosal melanoma at a high risk of treatment-related financial toxicity. Further research is needed to evaluate the efficacy of lower doses of immunotherapy, including its impact on long term outcomes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Se presenta el caso de un hombre de 77 años con melanoma mucoso metastásico, con limitación económica para recibir inmunoterapia a dosis estándar, quien fue tratado con nivolumab a una dosis más baja de 0.5 mg/kg cada dos semanas. Se demostró actividad del medicamento mediante una respuesta objetiva del tumor y la aparición de un evento adverso inmunomediado. Una menor dosis de nivolumab podría ser una alternativa en pacientes con melanoma mucoso avanzado con alta probabilidad de toxicidad económica secundaria al tratamiento. Se necesita más investigación para evaluar la eficacia y seguridad a largo plazo de menores dosis de inmunoterapia.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Melanoma]]></kwd>
<kwd lng="en"><![CDATA[Nivolumab]]></kwd>
<kwd lng="en"><![CDATA[Geriatric oncology]]></kwd>
<kwd lng="en"><![CDATA[Case report]]></kwd>
<kwd lng="en"><![CDATA[Financial toxicity]]></kwd>
<kwd lng="es"><![CDATA[Melanoma]]></kwd>
<kwd lng="es"><![CDATA[Nivolumab]]></kwd>
<kwd lng="es"><![CDATA[Oncología geriátrica]]></kwd>
<kwd lng="es"><![CDATA[Reporte de caso]]></kwd>
<kwd lng="es"><![CDATA[Toxicidad financiera]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Mehnert]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucosal Melanoma:Epidemiology, Biology and Treatment]]></article-title>
<source><![CDATA[Cancer Treat Res]]></source>
<year>2016</year>
<volume>167</volume>
<page-range>295-320</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mihajlovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vlajkovic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jovanovic]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stefanovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary mucosal melanomas:a comprehensive review]]></article-title>
<source><![CDATA[Int J Clin Exp Pathol]]></source>
<year>2012</year>
<volume>5</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>739-53</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altieri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Cockburn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucosal melanomas in the racially diverse population of California]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2017</year>
<volume>76</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>250-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Zeijl]]></surname>
<given-names><![CDATA[MCT]]></given-names>
</name>
<name>
<surname><![CDATA[Boer]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[van Poelgeest]]></surname>
<given-names><![CDATA[MIE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2020</year>
<volume>137</volume>
<page-range>127-35</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[Head and Neck Cancers (1.2023)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Namikawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshikawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma:a retrospective, multicenter study of 329 Japanese cases (JMAC study)]]></article-title>
<source><![CDATA[ESMO Open]]></source>
<year>2021</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>100325</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolchok]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Hoos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[O'Day]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2009</year>
<volume>15</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>7412-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodi]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Hwu]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kefford]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2016</year>
<volume>34</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1510-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Yousuf Zafar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Olver]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Financial Toxicity]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Springer, Cham ]]></publisher-loc>
<publisher-name><![CDATA[The MASCC Textbook of Cancer Supportive Care and Survivorship]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith, Grace]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Maria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Olivo, Pragati]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Advani, Matthew]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ning]]></surname>
</name>
<name>
<surname><![CDATA[Yimin Geng]]></surname>
</name>
<name>
<surname><![CDATA[Sharon]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
</name>
<name>
<surname><![CDATA[Robert Volk]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["Financial Burdens of Cancer Treatment:A Systematic Review of Risk Factors and Outcomes"]]></article-title>
<source><![CDATA[Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw 17.10]]></source>
<year>2019</year>
<page-range>1184-92</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Linking Intermediate to Final "Real-World" Outcomes:Is Financial Toxicity a Reliable Predictor of Poorer Outcomes in Cancer?]]></article-title>
<source><![CDATA[Curr Oncol]]></source>
<year>2022</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>2483-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poudyal]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Giri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tuladhar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Neupane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gyawali]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A survey in Nepalese patients with acute leukaemia:a starting point for defining financial toxicity of cancer care in low-income and middle-income countries]]></article-title>
<source><![CDATA[Lancet Haematol]]></source>
<year>2020</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>e638-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Román]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chavarri-Guerra]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Huicochea]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Financial Toxicity Among Older Mexican Adults With Cancer and Their Families:A Mixed-Methods Study]]></article-title>
<source><![CDATA[JCO Glob Oncol]]></source>
<year>2022</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[TSY]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Khong]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma:Experience in a resource-constrained setting]]></article-title>
<source><![CDATA[Hematol Oncol]]></source>
<year>2020</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>726-36</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Keam]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose nivolumab can be effective in non-small cell lung cancer:alternative option for financial toxicity]]></article-title>
<source><![CDATA[ESMO Open]]></source>
<year>2018</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kumarakulasinghe]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Muthu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-Dose Nivolumab in Renal Cell Carcinoma:A Real-World Experience]]></article-title>
<source><![CDATA[Oncology]]></source>
<year>2021</year>
<volume>99</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>192-202</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Khoueiry]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Sangro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Yau]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label, non-comparative, phase 1/2 dose escalation and expansion trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10088</numero>
<issue>10088</issue>
<page-range>2492-502</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Center for Drug Evaluation and Research</collab>
<source><![CDATA[Modification of the dosage regimen for nivolumab]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwarze]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Garaud]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jansen]]></surname>
<given-names><![CDATA[YJL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases:A Sequential Dual Cohort Phase II Clinical Trial]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2022</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>682</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joris]]></surname>
</name>
<name>
<surname><![CDATA[Sofie]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[«Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer:A Retrospective Case Series»]]></article-title>
<source><![CDATA[Anticancer Research, vol. 42, n.o 3]]></source>
<year>2022</year>
<page-range>1433-37</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Low]]></surname>
</name>
<name>
<surname><![CDATA[Jia]]></surname>
<given-names><![CDATA[Li]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[«Low-dose Pembrolizumab in the Treatment of Advanced Non-small Cell Lung Cancer»]]></article-title>
<source><![CDATA[International Journal of Cancer]]></source>
<year>2021</year>
<volume>149</volume>
<page-range>169-76</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patil]]></surname>
</name>
<name>
<surname><![CDATA[Vijay Maruti]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[«Low-Dose Immunotherapy in Head and Neck Cancer:A Randomized Study»]]></article-title>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2023</year>
<volume>41</volume>
<page-range>222-32</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
